Back to search

University of Crete (UOC)

Μελέτη της κινητικής και του φαινοτύπου κυκλοφορούντων καρκινικών κυττάρων ασθενών με μεταστατικό καρκίνο του μαστού που λαμβάνουν θεραπεία με eribulin mesylate

Abstract

dc:description

Breast cancer is the leading cause of cancer-related death among women worldwide. Understanding the mechanisms behind the metastatic process is crucial in improving treatments and enhancing patient survival. Many studies have focused on investigating tumor Epithelial-Mesenchymal-Transition (EMT), a dynamic process in which epithelial cells acquire a mesenchymal phenotype. This transformation increases metastatic capacity, provides cancer stem cell (CSC) properties, enhances metastatic potential, allows immune evasion, and contributes to treatment resistance. Eribulin mesylate is an anti-mitotic drug, that functions as a microtubule polymerization inhibitor, and it is used to treat metastatic breast cancer (MBC). Pre-clinical studies suggest that Eribulin may reverse the EMT state in breast cancer cells, target CSC subsets, and reduce immune evasion of cancer cells mediated by PDL1 (Programmed Death Ligand 1). However, limited clinical data regarding its effectiveness are still available. Obtaining consecutive cancer tissue biopsies for research can be invasive, challenging, and potentially dangerous. Therefore, there is growing interest in using circulating cancer cells (CTCs) analysis through «liquid biopsy», as a tool for identifying new biomarkers for cancer treatment. CTC detection is recognized as an adverse prognostic factor in patients with both early and metastatic BC. Data suggest that the phenotypic characterization of CTCs can provide additional prognostic and predictive information. This thesis aimed to investigate the frequency, number, and phenotype (EMT/CSC/PDL1) of CTCs in patients with MBC undergoing treatment with Eribulin, known for its anti-mitotic activity and its impact on EMT, cancer stem cell properties and PDL1-mediated immune evasion. Additionally, the prognostic and predictive significance of the presence and phenotype of CTCs in this study population was explored. To achieve this, we conducted a CTC analysis using peripheral blood samples from patients with MBC treated with Eribulin at the Oncology Department of the University Hospital of Heraklion. Samples were collected at various time points during treatment and at relapse. We also documented the patients' clinical and pathological characteristics, objective response, progression-free interval, and overall survival to explore potential clinical correlations with our findings. We investigated the presence, kinetics, and phenotype of CTCs for EMT markers (TWIST1) and CSC markers (ALDH1), using fluorescent microscopy. Our study included different time points: before treatment initiation, eight days following treatment, and during disease progression. The analysis revealed that baseline detection of CTCs (D1C1) is associated with an increased risk of disease progression and mortality in patients with MBC. Monitoring CTCs also provided valuable prognostic information beyond the initial assessment. Our results indicated that, early in eribulin treatment, CTCs temporarily lose their EMT characteristics while retaining their stem-like (CSC) features. The CSC phenotype is prominent during disease progression, suggesting its role in resistance to Eribulin. Additionally, we found that a CTC sub-population, CSC+/partially EMT+, is an independent adverse prognostic factor for patient outcomes. Although this sub-population initially disappears during Eribulin treatment, it reemerges at disease progression. To further investigate the mechanisms of action and resistance of Eribulin, we examined the role of the immune checkpoint PD-L1 (Programmed Death-Ligand 1) in CTCs, given its known association with the EMT state in breast cancer cells. Assessing both EMT and PD-L1 expression in the primary tumor is emerging as a potential prognostic marker in various cancer types, including breast cancer. While mesenchymal markers and PD-L1 expression have been identified separately in CTCs of breast cancer patients, their co-expression in CTCs of MBC patients has not been previously reported until this study. Therefore, we aimed to investigate the co-expression of these markers, in both single and cluster CTCs from a small group of patients treated with Eribulin, to determine any potential correlation with patient outcomes. We observed an early action of Eribulin on the CTC state and identified distinct mesenchymal CTC (mCTCs) subpopulations with poor prognosis, such as PD-L1+mCTCs, for the first time. This highlights the clinical significance of early phenotypic characterization of CTCs in exploring the mechanisms of resistance and disease progression in real-time during Eribulin treatment. In conclusion, this thesis suggests that the detection, phenotypic analysis, and continuous monitoring of CTCs are crucial for prognostic assessment in patients with MBC treated with Eribulin. Future research involving larger patient groups will be necessary to confirm the prognostic value of CTCs in these patients and assess their role in monitoring treatment efficacy. Reliable and easily accessible biomarkers could enhance the use of Eribulin in BC treatment. Based on the findings of this thesis, CTC-based assays could significantly contribute to this goal.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mala, Anastasia
  • Μαλά, Αναστασία

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/57727

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mala, Anastasia; Μαλά, Αναστασία. Μελέτη της κινητικής και του φαινοτύπου κυκλοφορούντων καρκινικών κυττάρων ασθενών με μεταστατικό καρκίνο του μαστού που λαμβάνουν θεραπεία με eribulin mesylate. University of Crete (UOC), 2024. http://hdl.handle.net/10442/hedi/57727